Modulators of alternative splicing as novel therapeutics in cancer

Sebastian Oltean

Alternative splicing (AS), the process of removing introns from pre-mRNA and re-arrangement of exons to give several types of mature transcripts, has been described more than 40 years ago. However, until recently, it has not been clear how extensive it is. Genome-wide studies have now conclusively shown that more than 90% of genes are alternatively spliced in humans. This makes AS one of the main drivers of proteomic diversity and, consequently, determinant of cellular function repertoire. Unsurprisingly, given its extent, numerous splice isoforms have been described to be associated with several diseases including cancer. Many of them have antagonistic functions, e.g., pro- and anti-angiogenic or pro- and anti-apoptotic. Additionally several splice factors have been recently described to have oncogene or tumour suppressors activities, like SF3B1 which is frequently mutated in myelodysplastic syndromes. Beside the implications for cancer pathogenesis, de-regulated AS is recognized as one of the novel areas of cell biology where therapeutic manipulations may be designed. This editorial discusses the possibilities of manipulation of AS for therapeutic benefit in cancer.

Key words: Novel cancer therapeutics; Splicing switching oligonucleotides; Alternative splicing; Small molecules; Splicing modulators

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Oltean S. Splicing therapeutics in cancer

World J Clin Oncol. 2015 Oct; 6(5): 92-95

INTRODUCTION

In the last years we have seen a plethora of anticancer agents that try to acquire more specific and targeted treatment in comparison with the conventional chemotherapies and radiotherapies used in the clinic. While it is highly unlikely they will be able to be used as mono-therapies on a large scale in oncology - due to the inherent problem of developing resistant clones as exemplified by the B-Raf inhibitor vemurafenib in melanoma[1], they have certainly proved very useful in combination therapies or as adjuvants that can improve overall survival in association with conventional therapies or reduce the doses used in chemo- and radiotherapies and therefore decrease side-effects.

Most of targeted anti-cancer drugs approved in clinical practice today are targeting receptor tyrosine kinases or cytoplasmic signalling molecules. However, since cancer cells are different from normal cells in virtually any property and function from DNA repair to regulating apoptosis or metabolism, theoretically drugs that hamper tumour growth may be designed at any level of gene regulation - transcriptional, post-transcriptional or post-translational. Indeed, recent years have produced intense research on potential new drugs (some already in trials or in the clinic) that are based on epigenetic modulation[2], DNA repair[3] or microRNAs[4] to name a few.

One level that has not been explored so far is represented by modulation of alternative splicing (AS).

AS

Splicing is the removal of introns during processing of pre-mRNA. Through AS the composition of the mature RNA may be changed through exon skipping, mutually exclusive exons, intron retention or 3’ and 5’ alternative splice sites[5]. AS has emerged in the post-genomic era as the main driver of proteome diversity with at least 94% of multi-exon genes being alternatively spliced in humans[6,7]. AS is one of the main control mechanisms for cell phenotype, and a process deregulated in disease. There are over 2000 splicing mutations known, involving 303 genes and implicated in 370 diseases[8]. Therefore it has become essential to study how this process is regulated, and how it can become deregulated in disease.

While the disease most commonly linked to deregulation of AS in several genes is cancer[9], there are many in-depth reports of pathogenic splice variants in diseases ranging from neuromuscular disorders[10] to diabetes[11] or cardiomyopathies[12].

AS IN CANCER - ASSOCIATED NOISE OR CAUSALITY?

An increasing amount of literature in the last years shows involvement of splicing in cancer and an incredible number of splice variants have been described to be associated with tumour progression - for recent reviews see[9,13,14]. For example, epidermal growth factor receptor, which is mutated in several cancers, has a splice variant that is missing exon 4 and is highly expressed in several cancers; this exon deletion makes the protein constitutively active[15]. K-Ras has two alternate exons - 4A and 4B - and depending on their inclusion/exclusion there is a strong differential association with various forms or localization of colon cancer[16]. The tumour suppressor p53 has two splice isoforms p53beta and p53gamma that result from two alternate exons; these isoforms modulate the activity of the main isoform and the way it regulates apoptosis in various contexts[17]. Finally, another notable example is the well-studied tumour suppressor retinoblastoma protein for which more than 15% of the mutations described in various cancers are related to splicing[18,19].

The main question that arises - especially having a therapeutic purpose in mind - are these modifications simply by-products of the oncogenic process or do they drive pathogenesis of cancer? While inevitably some splice variants are “associated noise” similar to physiology, there is compelling evidence for “pathogenic” AS in cancer.

Firstly, similar with mutations in transcription factors that denote many of them as oncogenes, there are mutations of spliceosome components or splice factors - e.g., SF3B1 in myelodysplastic syndromes[20].

Secondly, there is clear evidence of splicing-specific variants that may be induced by signalling in the cancer cell environment and result in acquired functions for the cancer cells that helps their pathogenic evolution. For example, while normal cells/tissues generally have a high level of the anti-angiogenic vascular endothelial growth factor A (VEGF-A) isoforms VEGF165a, this is lost in cancers, with expression of predominantly pro-angiogenic VEGF165b, which maintains a state of high and chaotic neovascularization in tumours[21]. However, no mutation has been identified so far that could account for this shift in the ratio of the two splice isoforms which is highly likely due to changes in the microenvironment during step-wise progression of the oncogenic process.

Finally, recent years have clearly shown that defective splicing contributes to one of the most challenging problems in oncology - acquired resistance to treatments. While there are numerous examples[22] we want to point out the well-known case of Vemurafenib. Patients treated with this drug invariably develop resistance. While several mechanisms have been described, in about a third of cases this occurs through faulty AS that results in truncated B-Raf which do not have the Ras-binding domain[23].
WILL SPLICING MODULATORS BE SPECIFIC?

Specificity is highly unlikely to be an important problem for SSOs, which are designed to bind on defined RNA sequences, though potential problems with delivery and toxicity might still be challenging.

SmSMs could potentially affect several other splice events regulated by the same splicing kinase or splicing factor intended to be modulating - however, the key issue is whether the manipulation of the intended targeted splice event is dominant functionally in the system/cell line of interest (i.e., the other splice events affected do not result in major unintended modifications in cell properties).

It is interesting to point-out a recent paper reporting the development of SmSMs of the SMN splicing and attenuation of spinal muscular atrophy[9]. The compounds were found in a screen using a splicing reporter that mimicked the endogenous splicing event. When an RNA-seq analysis was performed to assess specificity it was found that very few splice junctions are affected, therefore proving that specificity in splicing therapeutics using small molecules may be accomplished.

REFERENCES


